Simplify Asset Management Inc. Makes New $6.61 Million Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Simplify Asset Management Inc. purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 385,188 shares of the biotechnology company's stock, valued at approximately $6,606,000. ADMA Biologics accounts for about 0.3% of Simplify Asset Management Inc.'s portfolio, making the stock its 19th largest position. Simplify Asset Management Inc. owned approximately 0.16% of ADMA Biologics as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in ADMA. State Street Corp grew its stake in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock worth $259,970,000 after buying an additional 4,945,063 shares during the last quarter. Perpetual Ltd acquired a new position in ADMA Biologics in the 4th quarter worth about $62,300,000. Lord Abbett & CO. LLC bought a new position in ADMA Biologics in the third quarter valued at about $61,858,000. Allspring Global Investments Holdings LLC boosted its stake in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of ADMA Biologics during the fourth quarter valued at about $19,076,000. Institutional investors and hedge funds own 75.68% of the company's stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th.

Remove Ads

ADMA Biologics Trading Down 0.5 %

ADMA traded down $0.10 during midday trading on Tuesday, hitting $20.22. 2,396,202 shares of the company were exchanged, compared to its average volume of 3,363,541. The firm has a market capitalization of $4.78 billion, a P/E ratio of 72.21 and a beta of 0.60. The firm's 50 day moving average price is $16.84 and its 200-day moving average price is $18.07. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 1-year low of $5.90 and a 1-year high of $23.64.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.